future of glp-1 drugs Costs Explained: Managing Coverage Challenges GLP-1 Receptor Agonist Market: Exploring
Description
2023 [Google Scholar] 5.Do D., Lee T., Peasah S.K., Good C.B., Inneh A., Patel U
Risk of fracture with dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors in real-world use: systematic review and meta-analysis of observational studies
Jebb and colleagues are among the first to trace this trajectory
[15] This is the study we'll focus on, but the other studies cited above can be read for more background
R.HolscherC.GaultV
